Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Cold Spring Harbor Laboratory researchers reveal a groundbreaking approach using CAR T-cell therapy to rejuvenate aging ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...

Researchers have discovered a way to help aging intestines heal themselves using CAR T-cell therapy, targeting senescent ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important ...